SELECTION OF IMPROVED TUMOR REACTIVE T-CELLS

ABSTRACT

The present invention provides methods for preselecting TILs based on PD-1 expression, as well as methods for expanding those preselected PD-1 positive TILs in order to produce therapeutic populations of TILs with enhanced tumor-specific killing capacity (*e.g.*, enhanced cytotoxicity).

[Fig 171]